Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
about
Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis.Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of diseaseEfficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsEfficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.Biological therapies for psoriasis.Systemic therapies for psoriasis: an evidence-based update.Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials.The risk of deep fungal infections during biologic therapy for psoriasis.The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.Biological therapies in moderate and severe psoriasis: perspectives and certainties.Treatment of psoriasis with etanercept: the typical patient profile.Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis.Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre.Managing Scalp Psoriasis: An Evidence-Based Review.Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle.Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis.Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).[Psoriasis in special localizations].Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.Management of scalp psoriasis: current perspectives.
P2860
Q33574665-A105612B-726E-468C-B4F2-469A1BCDC333Q33625546-1F5833E1-E157-4A6A-A632-890983D5B26AQ33939033-0F0231F0-14AF-4789-B6E0-649394B88AE8Q35606402-36330A61-FC52-4E18-BD47-D61D479247D9Q35916032-445FAF8C-CAB3-497D-96A9-3653EF926745Q36184265-526A2260-583B-4A71-8F5F-E422F62B8C6BQ36190962-36E3E0DE-3233-4F88-971C-97934F3C4709Q38153077-6CFB0E44-A1C3-48BA-8B0C-1939913C7717Q38155648-B068FE43-3F48-485C-A7C0-C2B495E7B4D0Q38185297-389C9A79-D646-4C2C-8C7D-7049A95DBB9CQ38205035-C0643601-66B4-45AA-B7E4-509EA642B4ECQ38211315-54CA2EBB-1613-41E8-A50E-BDA551847CD1Q38219217-D22E8BD3-01DA-4793-863E-02CD65BBBF7BQ38235809-0112D14D-ED7A-4892-8F1A-0B627CB78941Q38419792-3CC32554-2C5B-439E-B6A8-4D6E3E736537Q38807058-3FADC4F3-46EF-44B9-8418-6A935B9AB579Q38841466-D59226BD-A2BD-4895-ABC4-AE816277CCDDQ38894423-E535DF8F-CF8F-4583-A34A-6D039E42064EQ38960080-080FABDA-A7F9-4D27-AC7D-4B31AEC5FD79Q41684920-EE94581C-46DB-4268-8E18-B84F31ABE73EQ41957838-33791B43-E96C-4B84-9C38-22D96D623581Q44773623-120D5762-D50C-48FE-8674-4DE320378E8DQ47260366-A5FAEBF4-561F-4849-B90A-FF535C073534Q48358207-DF9E05AB-528A-4339-A17B-A3750B872B13Q51375789-A2294A86-9299-4A2C-868B-925780A2D86CQ52851991-AF734D67-DBAC-4A96-95F2-31E9E24294C5Q54940383-5D1C58BA-69FA-45AA-B5D7-BEDC4548868FQ54941753-52B40845-9D2D-4DF2-9B38-498629F01102
P2860
Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Moderate to severe plaque psor ...... ontrolled study of etanercept.
@en
Moderate to severe plaque psor ...... ontrolled study of etanercept.
@nl
type
label
Moderate to severe plaque psor ...... ontrolled study of etanercept.
@en
Moderate to severe plaque psor ...... ontrolled study of etanercept.
@nl
prefLabel
Moderate to severe plaque psor ...... ontrolled study of etanercept.
@en
Moderate to severe plaque psor ...... ontrolled study of etanercept.
@nl
P2093
P1476
Moderate to severe plaque psor ...... ontrolled study of etanercept.
@en
P2093
Charles Lynde
Gregory Kricorian
Jerry Bagel
Paul Klekotka
Stephen Tyring
P356
10.1016/J.JAAD.2011.07.034
P407
P577
2011-10-20T00:00:00Z